University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background

Simple item page
dc.contributor.authorZhang, Cong
dc.contributor.authorShestopaloff, Konstantin
dc.contributor.authorHollis, Benjamin
dc.contributor.authorHei Kwok, Chun
dc.contributor.authorHon, Claudia
dc.contributor.authorHartmann, Nicole
dc.contributor.authorTian, Chengeng
dc.contributor.authorWozniak, Magdalena B
dc.contributor.authorSantos, Luis
dc.contributor.authorWest, Dominique M
dc.contributor.authorGardiner, Stephen
dc.contributor.authorMallon, Ann-Marie
dc.contributor.authorReadie, Aimee
dc.contributor.authorMartin, Ruvie
dc.contributor.authorNichols, Thomas
dc.contributor.authorBeste, Michael T
dc.contributor.authorZierer, Jonas
dc.contributor.authorFerrero, Enrico
dc.contributor.authorVandemeulebroecke, Marc
dc.contributor.authorJostins-Dean, Luke
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.date.accessioned2024-07-31T13:22:01Z
dc.date.available2024-07-31T13:22:01Z
dc.date.issued2023-10-05
dc.descriptionC.Z., C.H., N.H., C.T., M.W., A.R., R.M., M.T.B., J.Z., E.F., and M.V. are employees and stock owners of Novartis AG or its subsidiaries. Other authors, including K.S., C.H.K., L.S., D.W., and S.G. were funded by the BDI-Novartis Collaboration for AI in Medicine, which is funded by a grant from Novartis AG. Novartis AG manufactures and markets secukinumab and has an ongoing commercial interest in its success.en
dc.description.statusPeer revieweden
dc.format.extent8
dc.format.extent3076006
dc.identifier290728881
dc.identifier55d343f3-2b31-4eee-b692-1e6fd1722888
dc.identifier37659414
dc.identifier85173495119
dc.identifier.citationZhang, C, Shestopaloff, K, Hollis, B, Hei Kwok, C, Hon, C, Hartmann, N, Tian, C, Wozniak, M B, Santos, L, West, D M, Gardiner, S, Mallon, A-M, Readie, A, Martin, R, Nichols, T, Beste, M T, Zierer, J, Ferrero, E, Vandemeulebroecke, M & Jostins-Dean, L 2023, 'Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background', American Journal of Human Genetics, vol. 110, no. 10, pp. 1817-1824. https://doi.org/10.1016/j.ajhg.2023.08.010en
dc.identifier.doi10.1016/j.ajhg.2023.08.010
dc.identifier.iss10en
dc.identifier.issn0002-9297
dc.identifier.otherPubMedCentral: PMC10577077
dc.identifier.otherORCID: /0000-0003-3933-4967/work/164969062
dc.identifier.urihttps://hdl.handle.net/2164/23948
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85173495119&partnerID=8YFLogxKen
dc.identifier.vol110en
dc.language.isoeng
dc.relation.ispartofAmerican Journal of Human Geneticsen
dc.subjectbiological therapyen
dc.subjectclinical trialsen
dc.subjectgenome-wide association studiesen
dc.subjectinflammatory diseasesen
dc.subjectrheumatic diseasesen
dc.subjectHumansen
dc.subjectPsoriasis/drug therapyen
dc.subjectArthritis, Rheumatoid/drug therapyen
dc.subjectGenotypeen
dc.subjectArthritis, Psoriatic/drug therapyen
dc.subjectR Medicineen
dc.subjectGenetics(clinical)en
dc.subjectGeneticsen
dc.subjectSupplementary Informationen
dc.subject.lccRen
dc.titleResponse to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic backgrounden
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Zhang_etal_AJHS_Response_to_anti-IL17_VoR.pdf
Size:
2.93 MB
Format:
Adobe Portable Document Format
Download

Collections

All research

The Sir Duncan Rice Library

University of Aberdeen

Bedford Road

Aberdeen

AB24 3AA


Tel: +44 (0)1224 273330

Email: library@abdn.ac.uk

Share and keep up to date


FacebookTwitterWordpress